On July 3, 2025, IceCure Medical Ltd. announced preliminary financial results for the three and six months ended June 30, 2025. The company expects product sales of approximately $525,000 for the second quarter of 2025. This figure is lower than anticipated, contributing to product sales of approximately $1.25 million for the six months ended June 30, 2025, compared to $1.65 million in the prior year period.
The lower-than-expected second-quarter shipments were primarily due to temporary delays in certain non-U.S. customer shipments caused by the Israel-Iran conflict in June 2025. More than $200,000 of product sales scheduled for Q2 are now expected to be delivered and recognized in the third quarter of 2025. Payments for these delayed orders, mainly from global distributors outside the U.S., were received in Q2 and recorded as deferred sales.
The U.S. market was not impacted by these shipment delays due to sufficient inventory of ProSense® systems and probes maintained by IceCure in the region. The company reiterated that sales are expected to fluctuate quarter-over-quarter due to the timing of customer orders and shipments. IceCure plans to report its comprehensive Q2 and H1 2025 financial results in August 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.